Iron(III)-3-hydroxy-isonicotinamide Complexes for Iron Deficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current iron complexes for treating iron deficiency symptoms and anemias often suffer from low stability, solubility issues, and high toxicity, particularly with iron(II) salts causing oxidative stress, and polymeric complexes have limited oral application efficacy.
Innovation Solution
Development of iron(III)-3-hydroxy-isonicotinamide complex compounds with high water solubility and stability at neutral pH, allowing direct uptake into intestinal cells and release of iron without forming free iron ions, reducing oxidative stress and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If iron(II) salts are used for treating iron deficiency, then iron supplementation is achieved, but oxidative stress and high toxicity occur
Solution Approach 1:
The patent uses iron(III) complex compounds with 3-hydroxy-isonicotinamide ligands as intermediary compounds that deliver iron to the body without causing oxidative stress. These complexes act as mediators between the iron source and the body's iron metabolism, releasing iron in a controlled manner that avoids the harmful effects of direct iron(II) salt administration while maintaining therapeutic efficacy.
Solution Approach 2:
The invention changes the oxidation state parameter from iron(II) to iron(III) and modifies the chemical environment through specific ligand coordination. This parameter change transforms the properties of iron compounds, eliminating oxidative stress while preserving iron supplementation benefits. The complexes exhibit enhanced stability and reduced toxicity compared to traditional iron(II) salts.
2Quantity of substance
If polymeric iron complexes are used, then iron delivery is improved, but oral application efficacy is limited
Solution Approach 1:
The patent employs low-molecular-weight iron(III) complex compounds with specific local chemical properties that facilitate oral absorption. These compounds have optimized molecular characteristics including appropriate size, charge distribution, and ligand structure that enable them to interact effectively with intestinal transport mechanisms, overcoming the absorption limitations of polymeric complexes while maintaining stable iron delivery.
3Stability of the object's composition
If iron complexes are designed for high stability, then iron retention is improved, but solubility issues occur
Solution Approach 1:
The invention optimizes multiple parameters simultaneously: the oxidation state (iron(III)), the ligand structure (3-hydroxy-isonicotinamide with specific substituents), and the molecular weight. These parameter changes create a balance where the complexes maintain high stability through strong iron-ligand bonding while the specific ligand properties and molecular characteristics ensure adequate water solubility for oral administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The iron(III)-3-hydroxy-isonicotinamide complexes demonstrate enhanced iron utilization, faster therapeutic effects, reduced side effects, and improved stability, making them suitable for effective oral treatment of iron deficiency symptoms and anemias without the drawbacks of traditional iron salts.
Implementation Method 1
Development of iron(III)-3-hydroxy-isonicotinamide complex compounds with high water solubility and stability at neutral pH, allowing direct uptake into intestinal cells and release of iron without forming free iron ions
Data Source
AI summary
The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.